Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
ACS Infect Dis. 2021 Nov 12;7(11):2979-2986. doi: 10.1021/acsinfecdis.1c00458. Epub 2021 Oct 20.
Monocyclic β-lactams with antibiotic activity were first synthesized more than 40 years ago. Extensive early structure-activity relationship (SAR) studies, especially in the 1980s, emphasized the need for heteroatom activation of monocyclic β-lactams and led to studies of oxamazins, monobactams, monosulfactams, and monocarbams with various side chains and peripheral substitution that revealed potent activity against select strains of Gram-negative bacteria. Aztreonam, still the only clinically used monobactam, has notable activity against many Gram-negative bacteria but limited activity against some of the most problematic multidrug resistant (MDR) strains of and . Herein, we report that extension of the side chain of aztreonam is tolerated and especially that coupling of the side chain free acid with a bis-catechol siderophore mimetic significantly improves activity against the MDR strains of Gram-negative bacteria that are of most significant concern.
具有抗生素活性的单环 β-内酰胺类化合物在 40 多年前首次被合成。广泛的早期结构-活性关系(SAR)研究,尤其是在 20 世纪 80 年代,强调了单环 β-内酰胺类化合物需要杂原子活化,这导致了对氧马嗪、单酰胺类、单磺酰胺类和单碳酰胺类化合物的研究,这些化合物具有各种侧链和外围取代基,对革兰氏阴性菌的某些选择株具有很强的活性。氨曲南仍然是唯一临床应用的单酰胺类抗生素,对许多革兰氏阴性菌具有显著的活性,但对一些最具问题的多药耐药(MDR)菌株的活性有限。在此,我们报告称,氨曲南侧链的延长是可以耐受的,特别是将侧链游离酸与双儿茶酚类铁载体模拟物偶联,可以显著提高对革兰氏阴性菌 MDR 菌株的活性,这些菌株是最值得关注的。